Stay updated on Low Dose Ipilimumab With Pembrolizumab in Brain Metastases Clinical Trial
Sign up to get notified when there's something new on the Low Dose Ipilimumab With Pembrolizumab in Brain Metastases Clinical Trial page.

Latest updates to the Low Dose Ipilimumab With Pembrolizumab in Brain Metastases Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe NIH announcement banner about terminology changes has been removed. The page’s study-record error content is otherwise unchanged.SummaryDifference1%

- Check15 days agoChange DetectedThe displayed site revision updates from v3.7.2 to v3.8.0, while the study record continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check21 days agoChange DetectedA site-wide NIH notice announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence” and links to related updates and FAQs.SummaryDifference1%

- Check28 days agoChange DetectedThe ClinicalTrials.gov page remains a 403 Forbidden error page; its footer revision label changed from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check35 days agoChange DetectedThe ClinicalTrials.gov footer revision changes from v3.7.0 to v3.7.1 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check56 days agoChange DetectedThe page now shows a 403 Forbidden error page, replacing the previous detailed study record and navigation. This blocks access to the trial information and related resources on that page.SummaryDifference20%

Stay in the know with updates to Low Dose Ipilimumab With Pembrolizumab in Brain Metastases Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Low Dose Ipilimumab With Pembrolizumab in Brain Metastases Clinical Trial page.